Analytical Data
-
基因名
DEFb104
- Application
-
别名
DEFb104；DEFB104；DEFB4；DEFB104B；Beta-defensin 104
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q8WTQ1
-
表达区间
1-72aa
-
氨基酸序列
MQRLVLLLAISLLLYQDLPVRSEFELDRICGYGTARCRKKCRSQEYRIGRCPNTYACCLRKWDESLLNRTKP
-
分子量
8.5 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
DEFb104 is a recombinant protein that has garnered significant attention due to its potential therapeutic applications and its role in immune modulation. This protein is derived from the defensing family, which are small, cationic peptides known for their antimicrobial and immunoregulatory properties. Research into DEFb104 has focused on its mechanisms of action, structure, and potential benefits in treating various conditions, including infections and inflammatory diseases. Studies have shown that DEFb104 exhibits broad-spectrum antimicrobial activity, targeting a variety of pathogens, which makes it a candidate for developing novel antimicrobial therapies, especially in the face of rising antibiotic resistance. Additionally, its ability to influence immune responses positions DEFb104 as a potential agent in enhancing vaccine efficacy or acting as an immunotherapeutic agent in cancer treatment. Continued investigation into the stability, efficacy, and delivery methods of DEFb104 is essential to fully harness its therapeutic potential and address health challenges posed by resistant microbes and immune-related disorders. Overall, the exploration of DEFb104 highlights the intersection of protein engineering and clinical therapeutics, opening avenues for innovative treatments in infectious and inflammatory diseases.
